Avoro Capital Advisors LLC: KYMERA THERAPEUTICS INC (KYMR): Quarterly 13F Position History
As of Q1 2026, Avoro Capital Advisors LLC reported 7,474,747 shares of KYMERA THERAPEUTICS INC (KYMR), worth $622.6M and representing 6.1% of its 13F equity book. The position first appeared in Q3 2020 and has been disclosed across 23 13F-HR filings in Pactolio's tracked window.
- 7,474,747Shares Held (Latest Filing)
- $622.6MReported Market Value (Latest Filing)
- 6.1%Portfolio Weight (% of 13F Equity Book)
- 0Quarter-over-Quarter Share Change
- +$41.0MQuarter-over-Quarter Value Change
- 7,474,747Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 23 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 7,474,747 | 0 | — | $622.6M | 6.1% | $83.3 |
| Q4 2025 | 7,474,747 | +1,124,747 | +17.7% | $581.6M | 5.7% | $77.8 |
| Q3 2025 | 6,350,000 | 205,555 | -3.1% | $359.4M | 4.6% | $56.6 |
| Q2 2025 | 6,555,555 | +95,555 | +1.5% | $286.1M | 5.0% | $43.6 |
| Q1 2025 | 6,460,000 | +1,310,000 | +25.4% | $176.8M | 2.8% | $27.4 |
| Q4 2024 | 5,150,000 | +650,000 | +14.4% | $207.2M | 2.9% | $40.2 |
| Q3 2024 | 4,500,000 | +611,112 | +15.7% | $213.0M | 3.1% | $47.3 |
| Q2 2024 | 3,888,888 | 0 | — | $116.1M | 1.5% | $29.9 |
| Q1 2024 | 3,888,888 | +113,888 | +3.0% | $156.3M | 1.8% | $40.2 |
| Q4 2023 | 3,775,000 | 80,000 | -2.1% | $96.1M | 1.3% | $25.5 |
| Q3 2023 | 3,855,000 | 0 | — | $53.6M | 0.8% | $13.9 |
| Q2 2023 | 3,855,000 | 0 | — | $88.6M | 1.2% | $23.0 |
| Q1 2023 | 3,855,000 | +5,000 | +0.1% | $114.2M | 1.7% | $29.6 |
| Q4 2022 | 3,850,000 | +1,680,770 | +77.5% | $96.1M | 1.4% | $25.0 |
| Q3 2022 | 2,169,230 | +909,230 | +72.2% | $47.2M | 0.9% | $21.8 |
| Q2 2022 | 1,260,000 | +443,500 | +54.3% | $24.8M | 0.5% | $19.7 |
| Q1 2022 | 816,500 | +266,500 | +48.5% | $34.6M | 0.6% | $42.3 |
| Q4 2021 | 550,000 | +94,250 | +20.7% | $34.9M | 0.6% | $63.5 |
| Q3 2021 | 455,750 | +455,750 | — | $26.8M | 0.4% | $58.7 |
| Q2 2021 | 0 | 0 | — | $0 | 0.0% | — |
| Q1 2021 | 0 | 0 | — | $0 | 0.0% | — |
| Q4 2020 | 0 | 49,400 | -100.0% | $0 | 0.0% | — |
| Q3 2020 | 49,400 | — | — | $1.6M | 0.0% | $32.3 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Avoro Capital Advisors LLC first disclose a KYMR position in 13F-HR filings?
Avoro Capital Advisors LLC first reported KYMERA THERAPEUTICS INC (KYMR) on its 13F-HR filing for the period ending 2020-09-30 (Q3 2020). The position has appeared on 23 reported quarters within Pactolio's tracked window.
What was Avoro Capital Advisors LLC's most recent quarter-over-quarter share-count change in KYMR?
Avoro Capital Advisors LLC held the same 7,474,747 shares of KYMR between Q4 2025 and Q1 2026 — the reported share count was unchanged quarter-over-quarter.
Does the implied price-per-share represent Avoro Capital Advisors LLC's cost basis in KYMR?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.